Methods for treating inflammatory skin conditions (minocycline)
USPTO granted Journey Medical Corporation Patent US12594252B2 covering methods of treating inflammatory skin conditions using reduced-dose minocycline compositions. The patent, with 39 claims, names six inventors including Swati Kulkarni and Rajeev Singh Raghuvanshi. The invention relates to administering a pharmaceutical composition comprising a reduced dose of minocycline to achieve effective plasma or interstitial fluid concentrations for treating inflammatory skin conditions.
Patent US12594280B2: Antiviral Compositions for Influenza Treatment
USPTO granted Patent US12594280B2 to Universite Claude Bernard Lyon 1 covering antiviral pharmaceutical compositions containing Etilefrine and Diltiazem for preventing and treating influenza virus infections. The patent includes 10 claims and covers the use of these compounds in veterinary and pharmaceutical compositions.
Mitochondria-targeted atovagone compounds and methods for antitumor, antimicrobial, and antimalarial treatment
USPTO granted Patent US12594283B2 to The Medical College of Wisconsin, Inc. covering mitochondria-targeted Atovaquone compounds (Mito-ATO) and methods of using such compounds for antitumor, antimicrobial, and antimalarial treatment. The patent contains 22 claims and was filed on October 26, 2020.
Cambridge Cognition Patent - Combination Therapy for Schizophrenia
The USPTO granted Patent US12594270B2 to Cambridge Cognition Limited on April 7, 2026. The patent covers a combined therapy comprising alpha-7 nicotinic acetylcholine receptor activators with 5-HT3 receptor inhibitory activity combined with 5-HT3 receptor activators for treating schizophrenic disorders. The patent contains 21 claims and names Kiri Granger and Jennifer Barnett as inventors.
Benzalkonium Chloride for Treating COVID-19 and Conjunctivitis
USPTO granted patent US12594251B2 to Bausch + Lomb Ireland Limited on April 7, 2026, covering methods of treating COVID-19 (including ocular manifestations) and conjunctivitis using benzalkonium chloride, as well as methods for reducing COVID-19 transmission using the compound. The patent, with inventors Patrick McCormick and Kimberly Millard, contains 40 claims and is classified under CPC codes A61K 31/14, A61P 27/02, and A61P 31/14.
Small molecule compounds for treating lung epithelial and vascular endothelial cell injury
USPTO granted patent US12594282B2 to Guangzhou Cellprotek Pharmaceutical Co., Ltd. on April 7, 2026. The patent covers the use of 5α-androst-3β,5,6β-triol and analogues for treating pulmonary diseases mediated by lung epithelial cell injury and/or vascular endothelial cell injury. The compounds inhibit PFKFB3 expression and reduce vascular endothelial and alveolar epithelial cell injury.
SCYNEXIS patent for triterpenoid antifungals treating Pneumocystis pneumonia
The USPTO issued patent US12594266B2 to SCYNEXIS, INC. on April 7, 2026, covering eufumafungin derivative triterpenoid antifungal compounds and their use in treating or preventing Pneumocystis pneumonia (PCP). The patent includes 16 claims encompassing the compound structures, pharmaceutical compositions, and methods of treatment.
LILRB2 Antibodies and Uses Thereof - Cancer and Autoimmune Treatment
The USPTO granted patent US12596122B2 to The Board of Regents of the University of Texas System covering LILRB2 antibodies and their uses for detecting and treating cancer and autoimmune diseases. The patent names 11 inventors and includes 26 claims. The filing date was January 28, 2021, under application number 17759800.
BOL-148 substance abuse treatment method patent grant to Ceruvia Lifesciences
The USPTO granted patent US12594272B2 to Ceruvia Lifesciences LLC covering a method of treating substance abuse using 2-bromo-lysergic acid diethylamide (BOL-148). The patent contains 6 claims and was filed on March 25, 2021, with Carey Turnbull listed as the inventor.
Hydroflumethiazide composition for treating TNF-α-related diseases
USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.
Rhamnolipid compositions with antibiotics, UNC Chapel Hill patent
The USPTO granted patent US12594289B2 to The University of North Carolina at Chapel Hill on April 7, 2026, covering compositions combining biosurfactants (rhamnolipids) with antibiotics to enhance antibacterial potency against infections. The patent includes 18 claims and names Brian Conlon, Sarah Conlon, and Lauren Radlinski as inventors.
Prevention of tolerance to stimulant ADHD medication
USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.
Bexagliflozin extended-release tablet, SGLT2 inhibitor formulation
The USPTO granted patent US12594243B2 to TheracosBio, LLC for an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The patent covers formulations designed to achieve lower peak plasma concentrations (Cmax) compared to immediate-release forms while maintaining therapeutic drug levels over extended periods. The patent contains 7 claims and provides intellectual property protection for the drug delivery technology through 2040.
IL-17 antagonist compositions for treating inflammatory arthritis
USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.
Methods of treating psoriasis with secukinumab
The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.
MET Kinase Inhibitor Patent US12595245B2 Granted
The USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc. covering MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and methods of use for treating disease. The patent contains 18 claims and is classified under CPC codes C07D 401/12, C07D 215/22, C07D 405/14, and C07D 471/04. This grant establishes enforceable intellectual property rights for the disclosed MET kinase inhibitors.
Substituted pyrazolo piperidine carboxylic acids
USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.
PRMT5 inhibitors for cancer treatment
USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC covering PRMT5 inhibitor compounds of Formula I and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent includes 32 claims covering the compound compositions, methods of making, pharmaceutical formulations, and treatment methods.
Inhibitors of SARM1 for Axonal Degeneration Treatment
USPTO granted patent US12595252B2 to DISARM Therapeutics, Inc. on April 7, 2026, covering SARM1 inhibitor compounds and methods for treating axonal degeneration. The patent includes 4 claims and covers specific chemical compositions useful in neurological disease treatment.
CDER Interim Response Letter to Age Reversal Unity
FDA CDER issued an interim response letter to Age Reversal Unity regarding submission FDA-2025-P-4985, a Pre-Request for Designation (Pre-IND or similar drug development query). The letter provides preliminary feedback or requests additional information but does not constitute a final regulatory determination. The company must address agency concerns before a final response is issued.
FDA Administrative Practices and Procedures Information Collection Comment Request
The FDA published a notice in the Federal Register announcing an opportunity for public comment on a proposed information collection under the Paperwork Reduction Act of 1995. The collection covers general FDA administrative practices and procedures, including requests for formal hearings. Comments must be submitted by June 8, 2026 via regulations.gov or mail.
E2B(R3) Data Standards for Postmarketing Individual Case Safety Reports
FDA announces updated data standard requirements for postmarketing individual case safety reports (ICSRs) for human drug products, biological products, and drug- or biologic-led combination products. Starting October 1, 2026, all ICSR submissions to the FDA Adverse Event Monitoring System (AEMS) database via the Electronic Submissions Gateway Next Generation must use ICH E2B(R3) data standards, replacing the current E2B(R2) standard. The public comment period closes October 1, 2025.
FDA CTP Complaint - No Documents Available
The FDA Center for Tobacco Products (CTP) filed a formal complaint (FDA-2026-H-3091-0001) on regulations.gov. The docket indicates that a complaint has been initiated, though the underlying documents are not available for viewing. This represents a formal enforcement action by FDA's tobacco regulatory division against one or more regulated parties.
Variance Approval Letter to Primo Entertainment Inc
FDA's Center for Devices and Radiological Health (CDRH) approved a variance request from Primo Entertainment Inc, granting the company relief from specific regulatory requirements under federal standards for electronic products or radiation-emitting devices. The variance pertains to the company's entertainment products that fall under FDA's radiation safety jurisdiction.
Variance Application - Primo Entertainment Inc
FDA received a variance application from Primo Entertainment Inc (New York) on March 13, 2026. The application was submitted to the Center for Devices and Radiological Health (CDRH) for review. No associated documents are currently available for public viewing on the regulatory docket.
FDA confirms STRATTERA not withdrawn for safety
FDA confirms STRATTERA not withdrawn for safety
FDA Suitability Petition Amendment - Hyman Phelps & McNamara
Law firm Hyman, Phelps & McNamara, P.C. filed an amendment to a suitability petition with FDA's Center for Drug Evaluation and Research (CDER). The petition seeks a regulatory determination regarding drug product suitability under the Federal Food, Drug, and Cosmetic Act. FDA will review the amended petition and issue a determination on whether the requested drug product meets suitability requirements for approval pathways.
FDA Complaint - Tracking mno-s34f-ax16
FDA received a complaint filed on April 7, 2025, tracked under identifier mno-s34f-ax16 (docket FDA-2026-H-3442-0001). The complaint was submitted by CTP (Center for Tobacco Products) and is accessible via regulations.gov. No documents are currently available for viewing or download from the docket.
FDA Center for Tobacco Products Complaint Document
The FDA Center for Tobacco Products (CTP) filed a formal complaint document on April 7, 2026, via Regulations.gov docket FDA-2026-H-3303. The complaint, authored by CTP staff, initiates an enforcement proceeding against one or more regulated entities for alleged violations of federal tobacco product regulations. The specific allegations and parties involved are contained in the attachment but are not accessible for review in this summary.
Amended Citizen Petition - Insulin Detemir Drug Shortage and Biosimilarity Guidance
Alliance to Protect Insulin Choice submitted amendments to its citizen petition requesting FDA to declare insulin detemir a medically necessary drug in shortage, provide guidance on demonstrating biosimilarity for withdrawn drugs, and permit 503B outsourcing facilities to compound the drug. The petition addresses access concerns following detemir's withdrawal from the U.S. market.
FDA Issues Priority Review Voucher for LOARGYS (pegzilarginase-nbln)
The FDA announced issuance of a priority review voucher to Immedica Pharma AB for LOARGYS (pegzilarginase-nbln), approved February 23, 2026. The drug treats hyperargininemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency. The voucher was awarded under section 529 of the FD&C Act for rare pediatric disease products meeting specified criteria.
Vasopressin-2 receptor antagonist peptides and uses thereof
The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.
LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.
Anti-human P40 protein domain antibody and use thereof
USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).
Fc Variants and IL-8 Antibodies Patent Grant
USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.
Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant
USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.
Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes
The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.
P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims
P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims
Heterocyclic GLP-1 agonists
USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).
PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment
USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.
Amidines and amidine analogs for bacterial infection treatment
The USPTO granted Patent US12595251B2 to Georgia State University Research Foundation, covering amidine compounds and methods for treating bacterial infections or potentiating antibiotics. The patent names Binghe Wang, David W. Boykin, Manjusha Roy Choudhary, Arvind Kumar, Bingchen Yu, and Mengyuan Zhu as inventors. The patent, with 10 claims, covers CPC classifications including C07D compounds and A61P 31/04 (anti-infectives).
BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer
USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.
T cell receptors for mesothelin cancer immunotherapy
The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.
Aminopyridine compound as aldehyde trapping agent
USPTO granted Patent US12595259B2 to Zhuhai United Laboratories Co., Ltd. for an aminopyridine compound functioning as an aldehyde trapping agent, including formula (I) and its pharmaceutically acceptable salts. The patent covers 18 claims and has applications in ophthalmic therapeutics.
Substituted pyrimidine radical quenchers, Arizona State University
Substituted pyrimidine radical quenchers, Arizona State University
Anti-follicle stimulating hormone receptor antibodies and methods of treatment
USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.
Dosing regimes for treatment of synucleinopathies
USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.
Fluorine-containing compound and anti-cancer medical use thereof
The USPTO granted patent US12595275B2 to Ascentawits Pharmaceuticals, Ltd. on April 7, 2026, covering a fluorine-containing compound (Formula II/III) with anti-cancer medical applications. The patent claims novel structures incorporating trifluoromethyl groups and fluorine-substituted aryl or heteroaryl groups at specific positions, with 17 total claims.
CMS Proposes Skilled Nursing Facilities Payment Updates for FY 2027
CMS has published a proposed rule (CMS-1843-P) updating the Skilled Nursing Facility Prospective Payment System rates and policies for fiscal year 2027. The rule also proposes updates to the SNF Quality Reporting Program and SNF Value-Based Purchasing Program requirements. Comments must be submitted by June 1, 2026.
ASP Data Submission Notice for Medicare Part B Drugs - Comments Closed May 7
CMS published a 30-day Paperwork Reduction Act notice announcing revision of an existing collection for manufacturer submission of Average Sales Price (ASP) data for Medicare Part B drugs and biologicals. The notice revises the Bona Fide Service Fee Certification form and updates burden estimates. Comments on the information collection must be received by the OMB desk officer by May 7, 2026.
Medicare Prior Authorization WISeR Model Correction Notice
CMS issued a correction notice to fix typographical and technical errors in the July 1, 2025 Federal Register notice about the WISeR (Wasteful and Inappropriate Services Reduction) Model for Medicare prior authorization. The corrections update specific lists of procedure codes for epidural steroid injections, vertebral compression fracture procedures, fusion procedures, and apnea treatments, while also clarifying applicability language for skin and tissue substitutes. The corrections are effective April 6, 2026, with applicability to January 1, 2026.
Medline Convenience Kits containing Namic RA Syringes recall - death risk
Health Canada issued a Type I recall for Medline Convenience Kits containing Namic RA Syringes due to a potential risk of the syringe rotating adaptor unwinding during use, which may cause procedural delays or, in severe cases, death. Multiple lot numbers across angiographic kits, convenience kits, and tumescent syringe kits are affected. Healthcare providers have been advised to immediately stop using and discard the affected syringes.
CMS FY 2027 IPF proposed rule, comment deadline June 1
CMS FY 2027 IPF proposed rule, comment deadline June 1
Movement of Plants and Plant Products from Hawaii and the Territories - Information Collection Extension
APHIS is requesting public comment on a revision to and extension of approval for information collection associated with regulations for interstate movement of fruits and vegetables from Hawaii and the Territories. The collection covers activities including limited permits, inspections, transit permits, compliance agreements, certification, and recordkeeping under OMB Control Number 0579-0346. Comments are due by June 8, 2026.
2027 Medicare Advantage and Part D Rate Announcement
CMS released the CY 2027 Medicare Advantage and Part D Rate Announcement, finalizing capitation rates and payment policies. The final policies result in a 2.48% average payment increase, representing over $13 billion in additional payments to Medicare Advantage plans. The announcement includes risk model revisions, Star Ratings changes, and updated normalization factors affecting plan payment calculations.
CMS Finalizes 2027 Medicare Advantage and Part D Payment Policies
CMS released the Calendar Year 2027 Medicare Advantage and Part D Rate Announcement, finalizing payment policies projected to result in a net average increase of 2.48%, representing over $13 billion in additional MA payments. The finalized policies address coding differentials between MA and Original Medicare and establish three guiding principles for risk adjustment: simplicity, competition, and payment accuracy.
Amide EZH2 Inhibitor Patent - Preparation Method and Medical Applications
The USPTO granted patent US12595267B2 to Shanghai Synergy Pharmaceutical Sciences Co., Ltd. covering an amide small molecule compound that inhibits EZH2 (Zeste gene enhancer homolog 2). The patent protects methods for preparing the compound and its use in treating EZH2-mediated diseases including tumors, myeloproliferative diseases, and autoimmune diseases. The patent contains 11 claims and names 19 inventors.
Benzo nitrogen-containing heteroaromatic ring derivative for complement factor B treatment
The USPTO granted patent US12595270B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a benzo nitrogen-containing heteroaromatic ring derivative (general formula I) and its use in treating diseases associated with complement factor B activity or expression. The patent includes 8 claims encompassing the compound, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutically acceptable salts or co-crystals.
Acid anhydride compound, polyamideimide resin and film
USPTO granted Patent US12595268B2 to Korea Advanced Institute of Science and Technology (KAIST) for a novel acid anhydride compound and polyamideimide resin and film utilizing the same. The invention provides high thermal resistance, low coefficient of thermal expansion, and colorless transparency properties. The patent contains 11 claims and was filed under Application No. 18517326.
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease
The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.
Means and methods for detecting soy allergens
The USPTO granted Patent US12596111B2 to Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. covering methods for manufacturing antibodies that specifically bind to soy Gly m 8 protein and methods for detecting soy material in food or feedstuff preparations using said antibodies. The patent includes 12 claims and covers antibody production via plant-based protein expression, particularly in tobacco plants.
Analyte Detection Immunoassay Patent Grant
USPTO granted Promega Corporation patent US12596119B2 covering compositions, kits, and methods for performing analyte detection immunoassays. The patent contains 11 claims and lists inventors Nidhi Nath, Rod Flemming, and Marjeta Urh. The patent application was filed on April 26, 2022.
Monoclonal antibody matrix metalloproteinase-1 patent granted
USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.
TfR1 Humanized Antibodies and Cancer Treatment Methods
The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.
GPC3 antibody patent - methods of use for cancer treatment
The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.
CLDN18.2 binding molecule patent granted to Sanyou
CLDN18.2 binding molecule patent granted to Sanyou
TREM2 stabilizing antibodies, Novartis AG, patent grant
The USPTO granted Patent US12595305B2 to Novartis AG on April 7, 2026, covering antibodies that bind to and stabilize human TREM2 protein. The patent names nine inventors and includes 10 claims, establishing Novartis's exclusive rights to this antibody technology.
6-Thio-dG Treatment for Pediatric Brain Tumors
The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.
CDC NNDSS Surveillance Update, Comment Deadline June 8
The CDC published a surveillance update to the National Notifiable Diseases Surveillance System (NNDSS), with public comments requested by June 8. The NNDSS is a nationwide system for tracking notifiable diseases reported by state and territorial health departments. Healthcare providers, laboratories, and public health authorities submitting disease data to CDC should review the proposed changes and submit feedback.
CDC Drug Overdose Data Collection - Comment Request
The CDC has issued a consultation document requesting public comments on drug overdose data collection methods and reporting requirements. The document seeks input on proposed data collection standards that state and local health departments would use to report overdose surveillance data to the CDC. Comments are due by June 8th.
Bispecific CAR Targeting CD19 and CD20 for Cancer Treatment
USPTO granted Patent US12594321B2 to Novartis AG for a bispecific chimeric antigen receptor (CAR) targeting CD19 and CD20 for cancer treatment. The patent covers CAR proteins, encoding nucleic acids, vectors, and methods for treating diseases associated with CD20 or CD22 expression using modified T or NK cells. The patent includes 18 claims and lists 6 inventors.
Quorum Sensing Compositions and Methods for Microbial Community Modulation
USPTO granted patent US12594307B2 to The Regents of the University of California for quorum sensing compositions and methods for modulating bacterial quorum sensing. The patent covers engineered bacterial strains with multiple activator polypeptide-encoding sequences and methods for tunable dynamics in microbial communities. Inventors include Jeff Hasty, Arianna Miano, and Michael Julius Liao, with applications spanning synthetic biology and therapeutic development.
Temperature-Optimized Bacillus Strains Patent Grant
The USPTO granted patent US12593849B2 to Chr. Hansen A/S on April 7, 2026, covering new strains of Bacillus paralicheniformis with improved growth rates and plant growth promoting properties. The patent names six inventors including Patricia Dominguez Cuevas and Lars Moelbak, with 21 claims. Filing date was August 28, 2020, under application number 17638152.
Single domain antibodies for cancer therapy, Institut Curie
USPTO granted Patent US12594302B2 to Institut Curie covering fully humanized anti-FGFR4 single domain antibodies (sdAbs), functionalized drug nanocarriers, and compositions for cancer therapy. The patent includes 24 claims and covers nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The invention relates to FGFR4-targeted therapies for treating cancer.
Virus-like Particles Patent Granted to University of Denver
The USPTO granted Patent US12594329B2 to the University of Denver on April 7, 2026. The patent covers virus-like particles, compositions, antibody detection tests using virus-like particles, and methods of producing non-replicating virus-like particles from modified viral genomes. Schuyler B. van Engelenburg is the sole inventor of the 9-claim patent.
CD8-specific capture agents, compositions, and methods of using and making
The USPTO granted Regeneron Pharmaceuticals patent US12594350B2 covering stable peptide-based CD8 capture agents for use as detection agents. The patent was issued April 7, 2026, naming Regeneron Pharmaceuticals, Inc. as assignee and Heather Dawn Agnew and Bert Tsunyin Lai as inventors. The application, filed April 4, 2017 (Application No. 15478596), contains 13 claims.
Exosome Production Method for Cancer Therapeutic Delivery
USPTO granted patent US12594344B2 to China Medical University for a large-scale exosome production method using cyclic tensile bioreactors. The patent covers exosomes with anti-HLA-G protein configured as delivery vehicles for cancer therapeutic agents. The grant includes 10 claims and applies to A61P 35/00 (antineoplastic agents) and related CPC classifications.
Probiotics to prevent cognitive dysfunction
USPTO granted patent US12593863B2 to INTERNATIONAL N&H DENMARK APS covering the use of Lacticaseibacillus paracasei bacteria for preventing or treating cognitive impairments, including those induced by sleep deprivation. The patent names Sile Griffin, Elaine Patterson, and Markus Lehtinen as inventors and includes 5 claims.
Cisplatin-Eugenol Analogue for Cancer Treatment
The USPTO granted Patent US12594338B2 to King Faisal Specialist Hospital & Research Centre for a cisplatin-eugenol compound with anti-cancer properties. The patent covers the compound composition, synthesis method, pharmaceutical formulations, and methods of cancer treatment. Inventors include Abdelilah Aboussekhra, Ibrahim Al-Jammaz, Basem Al-Otaibi, and Noura N. Alraouji. The patent was filed on July 27, 2023.
Nanoparticulate drug delivery for therapeutic applications
The USPTO granted Patent US12594347B2 to Duke University for compositions comprising self-assembling conjugates designed for nanoparticulate drug delivery. The patent covers conjugates with albumin binding domains and molecules having log D ≥ 1.5 at pH 7.4, intended for therapeutic applications including cancer treatment (A61P 35/00). Assignee: Duke University; Inventors: Parisa Yousefpour, Ashutosh Chilkoti.
Topiramate oral liquid suspension patent granted
USPTO granted patent US12594241B2 to inventors Paul Sudhakar and Scott Boyer for an oral liquid suspension formulation containing topiramate (Application No. 18462651). The patent contains 29 claims covering the composition and methods of medical treatment using the formulation. Generic and branded pharmaceutical manufacturers should assess this patent for potential freedom-to-operate implications.
HIV Oral Drug Composition Patent
The USPTO granted Patent US12594244B2 to Gilead Sciences, Inc. covering a solid oral dosage form combining tenofovir alafenamide, emtricitabine, and a compound of Formula I for HIV treatment. The patent contains 29 claims and was granted on April 7, 2026, with a filing date of September 29, 2025.
Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors
USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.
Mesembrine Crystalline Salt Patent Grant
USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.
MDM2 Inhibitor Patent Granted to Bahcesehir University
The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.
2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent
USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.
STAT3 inhibitor prodrug patent compositions
USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.
Thiosemicarbazates and Uses Thereof
The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.
Fresenius Dali 750 Kit Hemadsorption Device Safety Notice
ANSM issued a safety alert regarding a field safety corrective action conducted by Fresenius Medical Care AG for the Dali 750 Kit hemadsorption device. The safety action is registered under reference R2608923. Users of this medical device have received direct correspondence from Fresenius with details of the corrective measure.
Siemens Atellica CH CK_L Creatine Kinase Reagent Recall
ANSM has recorded a product recall by Siemens Healthcare Diagnostics for its Atellica CH Creatine Kinase (CK_L) biochemical reagent. The recall affects 847 units distributed to medical biology laboratories. This safety action is registered as ANSM reference number R2609472, with the manufacturer issuing recall correspondence on 07/04/2026.
Annual EPSDT Participation Report Information Collection
CMS published a 30-day notice under the Paperwork Reduction Act announcing revisions to Form CMS-416, the Annual Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Participation Report. The collection assesses state effectiveness in providing early health screening, diagnostic, and treatment services to eligible Medicaid children. Public comments on the burden estimate are due May 6, 2026.
Physician Certifications/Recertifications in Skilled Nursing Facilities
CMS published a notice announcing a 60-day public comment period for an extension of an existing information collection regarding physician certifications and recertifications in skilled nursing facilities. The collection is required under Section 1814(a) of the Social Security Act for Medicare payment certifications. Comments on burden estimates are due June 5, 2026.
Administrative Practices and Formal Hearings Information Collection
FDA issued a notice seeking public comment on an information collection request regarding administrative practices and formal hearings. The agency is requesting feedback on how it manages formal hearing procedures and administrative processes. Comments must be submitted by June 8, 2026.
Priority Review Voucher for LOARGYS Rare Pediatric Disease Product
FDA issued a priority review voucher to Aeglea BioTherapeutics for LOARGYS (pegzilarginase-nbln), a rare pediatric disease product designated for arginase deficiency. This voucher grants the holder priority FDA review for a future drug marketing application and is transferable. The document is a routine notice under the Rare Pediatric Disease Priority Review Voucher Program.
Rural Health Care Services Outreach Program Measures
HRSA is seeking public comments on proposed measures for the Rural Health Care Services Outreach Program under OMB No. 0906-0009-Revision. The notice requests input on information collection requirements affecting entities participating in rural health outreach. Comments must be submitted by June 8, 2026.
Information Collection Activities Submission for OMB Review
CMS published a notice submitting information collection activities to OMB for review under the Paperwork Reduction Act. The notice solicits public comments on proposed and existing data collection requirements administered by the agency. Regulated parties have 30 days to submit comments.
Proposed Data Collection Submitted for Public Comment
The CDC has published a notice in the Federal Register proposing a new data collection for public comment. The notice invites feedback from the public and relevant stakeholders on the proposed collection. Comments must be submitted by June 8, 2026.
WTC Health Program Denies Petitions on Hepatic Steatosis
The CDC's World Trade Center Health Program Administrator has denied Petitions 029, 034, 035, and 062, which requested the addition of hepatic steatosis (fatty liver disease) as a covered health condition under the program. The finding of insufficient evidence was published in the Federal Register (91 FR 17650). This decision affects WTC responders and survivors seeking coverage for this condition.
Proposed Data Collection Under Paperwork Reduction Act
The CDC published a Federal Register notice seeking public comments on a proposed data collection under the Paperwork Reduction Act. The notice requests input on information collection burden hours and related requirements. Comments must be submitted by June 8, 2026.
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention published a routine Paperwork Reduction Act notice seeking public comment on agency information collection requirements. The notice announces a 30-day comment period for unspecified CDC forms. No new compliance obligations are created by this administrative procedure.
Plant Product Movement Information Collection Request
APHIS is requesting OMB approval to revise and extend its information collection related to the movement of plants and plant products from Hawaii and US Territories. This Paperwork Reduction Act notice invites public comment on the proposed information collection requirements, with comments due by June 8, 2026.
IVascular Navitian Coronary Microcatheter Recall
ANSM issued a medical device safety recall (R2607706/R2609369) for IVascular Navitian coronary microcatheters manufactured by Life Vascular Device Biotech S.L. The recall affects specific lots and targets pharmacies and healthcare establishments in France. Users should immediately quarantine and return affected products following the manufacturer's instructions.
Ladder Safety System Deadline Removal
OSHA has published a proposed rule to remove the compliance deadline requiring fixed ladders exceeding 24 feet above a lower level to be equipped with personal fall arrest systems or ladder safety systems. The agency is accepting public comments until June 5, 2026 on whether to repeal or revise the personal fall arrest system requirement and instead permit employers to continue using ladder cages or wells.